Pfizer (NYSE:PFE) Shares Down 2.4% – Here’s Why
by Doug Wharley · The Cerbat GemPfizer Inc. (NYSE:PFE – Get Free Report) was down 2.4% during mid-day trading on Tuesday . The stock traded as low as $26.35 and last traded at $26.60. Approximately 41,308,666 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 48,049,133 shares. The stock had previously closed at $27.26.
Pfizer News Roundup
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Late-stage oncology progress: Phase 3 data showing PADCEV + Keytruda reduced recurrence/death risk in muscle‑invasive bladder cancer and full FDA approval for a BRAFTOVI regimen in BRAF V600E metastatic colorectal cancer strengthen Pfizer’s oncology growth story and revenue diversification. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
- Positive Sentiment: Early pipeline expansion: Pfizer reported progress on PF‑07328948 (kidney function Phase 1 study), which, while early, supports long‑term pipeline value and future specialty drug upside. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
- Positive Sentiment: Analyst support: Argus upgraded Pfizer from Hold to Buy and set a $35 price target, adding a bullish institutional view that could attract buyers into the stock. Argus Upgrade Coverage (Benzinga)
- Neutral Sentiment: Cash flow narrative: Commentary and analysis pieces highlight improving cash generation and dividend appeal (6%+ yield), which supports income‑oriented investor interest but is not an immediate catalyst. Pfizer’s Quiet Cash Comeback
- Neutral Sentiment: Industry tech tailwind: Reports on AI adoption in pharma manufacturing name Pfizer among firms integrating AI for efficiency; this supports medium‑term margin and manufacturing competitiveness but is diffuse as an earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
- Negative Sentiment: Regulatory friction: CEO Albert Bourla publicly flagged issues with the FDA’s vaccine leadership, raising concerns about regulatory relations and potential delays for vaccine programs. Pfizer CEO flags issues with FDA’s vaccine leadership
- Negative Sentiment: Product setback: Pfizer withdrew its Zumrad EMA filing, a direct near‑term regulatory setback that can subtract from near‑term approval upside and weigh on sentiment. Pfizer withdraws Zumrad EMA filing
Analyst Ratings Changes
A number of research firms recently weighed in on PFE. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Royal Bank Of Canada began coverage on Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.05.
Get Our Latest Research Report on PFE
Pfizer Stock Performance
The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a fifty day simple moving average of $26.17 and a 200-day simple moving average of $25.43. The company has a market capitalization of $151.25 billion, a P/E ratio of 19.56 and a beta of 0.47.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company posted $0.63 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.
Institutional Trading of Pfizer
Several large investors have recently made changes to their positions in PFE. NWF Advisory Services Inc. increased its position in Pfizer by 9.3% in the 4th quarter. NWF Advisory Services Inc. now owns 36,708 shares of the biopharmaceutical company’s stock valued at $914,000 after acquiring an additional 3,124 shares in the last quarter. Reflection Asset Management bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $148,000. CFO Capital Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $454,000. Tobam bought a new position in Pfizer in the 4th quarter worth approximately $382,000. Finally, Corecam Pte. Ltd. lifted its holdings in Pfizer by 2.8% during the 4th quarter. Corecam Pte. Ltd. now owns 289,630 shares of the biopharmaceutical company’s stock worth $7,212,000 after buying an additional 7,900 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.